AstraZeneca PLC (AZN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...
Investor's Business Daily on MSN
AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat
AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...
CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...
Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...
Investing.com -- AstraZeneca PLC (ST:AZN) announced Tuesday that its drug Koselugo (selumetinib) has received European Union ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
WASHINGTON (AP) — AstraZeneca on Friday became the second major pharmaceutical manufacturer to announce it had agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the ...
Acknowledging China’s innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is confident about further investing in the country, and working with local ...
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC ...
AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, ...
AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results